A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

Zhichen Sun; Zhenhua Ren; Kaiting Yang; Zhida Liu; Shuaishuai Cao; Sisi Deng; Lily Xu; Yong Liang; Jingya Guo; Yingjie Bian; Hairong Xu; Jiyun Shi; Fan Wang; Yang-Xin Fu; Hua Peng

doi:10.1038/s41467-019-11782-w

Nature Communications (Aug 2019)

A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

Zhichen Sun,
Zhenhua Ren,
Kaiting Yang,
Zhida Liu,
Shuaishuai Cao,
Sisi Deng,
Lily Xu,
Yong Liang,
Jingya Guo,
Yingjie Bian,
Hairong Xu,
Jiyun Shi,
Fan Wang,
Yang-Xin Fu,
Hua Peng

Affiliations

Zhichen Sun: Key Laboratory of Infection and Immunity of CAS, Institute of Biophysics, Chinese Academy of Sciences
Zhenhua Ren: Department of Pathology, University of Texas Southwestern Medical Center
Kaiting Yang: Key Laboratory of Infection and Immunity of CAS, Institute of Biophysics, Chinese Academy of Sciences
Zhida Liu: Department of Pathology, University of Texas Southwestern Medical Center
Shuaishuai Cao: Key Laboratory of Infection and Immunity of CAS, Institute of Biophysics, Chinese Academy of Sciences
Sisi Deng: University of Chinese Academy of Sciences
Lily Xu: Department of Biological Sciences, University of Wellesley College
Yong Liang: Key Laboratory of Infection and Immunity of CAS, Institute of Biophysics, Chinese Academy of Sciences
Jingya Guo: Key Laboratory of Infection and Immunity of CAS, Institute of Biophysics, Chinese Academy of Sciences
Yingjie Bian: Key Laboratory of Infection and Immunity of CAS, Institute of Biophysics, Chinese Academy of Sciences
Hairong Xu: Key Laboratory of Infection and Immunity of CAS, Institute of Biophysics, Chinese Academy of Sciences
Jiyun Shi: Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences
Fan Wang: Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences
Yang-Xin Fu: Department of Pathology, University of Texas Southwestern Medical Center
Hua Peng: Key Laboratory of Infection and Immunity of CAS, Institute of Biophysics, Chinese Academy of Sciences

DOI: https://doi.org/10.1038/s41467-019-11782-w
Journal volume & issue: Vol. 10, no. 1
pp. 1 – 12

Abstract

Read online

Interleukin-2 (IL-2) based cancer therapy is limited by severe toxicity and strong Treg amplification at the therapeutic dosage. Here, the authors develop a recombinant IL-2 immunocytokine which is comprised of a tumor-targeting antibody fused to a super mutant IL-2 and show in mouse models that this next-generation IL2 has reduced toxicity and enhanced antitumor activity.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal